DEA final telehealth prescribing rule awaits White House review

The DEA has reportedly sent a final telehealth prescribing rule to the White House after years of temporary measures. Its scope, safeguards, effective date, and provisions for established chronic-pain patients remain unknown; eventual limits could affect CRPS/RSD patients lacking local opioid-prescribing specialists. No actionable rule change is confirmed.